"Results shown that the previously reported association of an ACYP2 variant with cisplatin-induced hearing loss in pediatric brain tumor patients could be replicated in an independent cohort of patients with osteosarcoma. Therefor the ACYP2 variant should be considered a predictor of cisplatin-induced hearing loss in patients with osteosarcoma or other solid tumors"xsd:string